Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 229 (6%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3283 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (13%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-MIDODRINE | 2.5MG | TABLET | Resolved | 2024-02-09 | 2024-05-24 | 219162 |
| APO-MIDODRINE | 2.5MG | TABLET | Resolved | 2025-10-24 | 2025-10-31 | 270270 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2017-03-10 | 2017-05-10 | 393 |
| APO-MIRTAZAPINE | 45MG | TABLET | Resolved | 2017-03-10 | 2017-03-23 | 396 |
| APO-MIRTAZAPINE | 15MG | TABLET | Resolved | 2017-03-22 | 2017-05-02 | 3909 |
| APO-MIRTAZAPINE | 15MG | TABLET | Resolved | 2017-05-04 | 2017-06-15 | 8874 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2017-05-16 | 2017-06-15 | 10429 |
| APO-MIRTAZAPINE | 45MG | TABLET | Resolved | 2017-06-08 | 2017-08-08 | 12358 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2017-07-11 | 2017-10-17 | 15370 |
| APO-MIRTAZAPINE | 15MG | TABLET | Resolved | 2017-08-14 | 2017-10-03 | 19226 |
| APO-MIRTAZAPINE | 45MG | TABLET | Resolved | 2017-10-03 | 2017-10-17 | 24271 |
| APO-MIRTAZAPINE | 15MG | TABLET | Resolved | 2018-01-10 | 2018-03-25 | 35545 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2018-01-17 | 2018-03-25 | 36316 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2018-05-23 | 2018-08-18 | 50156 |
| APO-MIRTAZAPINE | 15MG | TABLET | Resolved | 2018-06-04 | 2018-09-29 | 51204 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2019-01-09 | 2019-02-01 | 71676 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2019-03-05 | 2019-04-05 | 77893 |
| APO-MIRTAZAPINE | 15MG | TABLET | Resolved | 2020-01-08 | 2020-02-10 | 102572 |
| APO-MIRTAZAPINE | 15MG | TABLET | Resolved | 2020-04-13 | 2020-04-27 | 111921 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2020-11-19 | 2020-12-28 | 128612 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |